No Filler Here

Allergan Inc. s a health care co. that develops pharmaceuticals, biologics and medical devices. The Company’s segments include ophthalmic products; Botox for therapeutic and aesthetic indications; skin care products; urologic products and medical devices.

[PostStockWidget stock_valuation="" pricetype="live" manual_date="Dec. 21, 2012, 2:04pm GMT" symbolcodes="'AGN'" symbolprices="65" div_align="right"]

• We identified a low valuation in Allergan under $91 just a few weeks ago. At the time we identified a high valuation target of $110 in 12 - 18 months.

• With the rapid rise in the market to finish the year, we have reached our high valuation target much faster than expected. We are exiting now and will wait for the next opportunity.

• Total return on this trade +21.0% in less than two months

• HIGH VALUATION IN ALLERGAN AT $110.00 (AGN-US, $109.90) FULL POSITION

P/E: 19.8X DIV: $.20 (.22%) MKT CAP: $27B Debt:Nil (Cash:$1.3B) RETURN ON CAPITAL: 39.5% EARNINGS YIELD: 6.3% 5 YR EPS Growth rate*:13.3% P/E/G Ratio: 1.55X EPS: $4.58 2014 EST.: $5.41 2015 EST.: $5.85